Efficacy and Safety of a Once-Daily Fixed-Dose Combination of Abacavir/Lamivudine Compared With Abacavir Twice Daily and Lamivudine Once Daily as Separate Entities in Antiretroviral-Experienced HIV-1 -Infected Patients (CAL30001 Study).

MLA

LaMarca, Anthony, et al. “Efficacy and Safety of a Once-Daily Fixed-Dose Combination of Abacavir/Lamivudine Compared With Abacavir Twice Daily and Lamivudine Once Daily as Separate Entities in Antiretroviral-Experienced HIV-1 -Infected Patients (CAL30001 Study).” JAIDS: Journal of Acquired Immune Deficiency Syndromes, vol. 41, no. 5, Apr. 2006, pp. 598–606. EBSCOhost, https://doi.org/10.1097/01.qai.0000214821.33905.5c.

APA

LaMarca, A., Clumeck, N., Plettenberg, A., Domingo, P., Kaisong Fu, Craig, C., Zhao, H., Watson, M., Gordon, D., & Scott, T. (2006). Efficacy and Safety of a Once-Daily Fixed-Dose Combination of Abacavir/Lamivudine Compared With Abacavir Twice Daily and Lamivudine Once Daily as Separate Entities in Antiretroviral-Experienced HIV-1 -Infected Patients (CAL30001 Study). JAIDS: Journal of Acquired Immune Deficiency Syndromes, 41(5), 598–606. https://doi.org/10.1097/01.qai.0000214821.33905.5c

Chicago

LaMarca, Anthony, Nathan Clumeck, Andreas Plettenberg, Pere Domingo, Kaisong Fu, Charles Craig, Henry Zhao, Maria Watson, David Gordon, and Trevor Scott. 2006. “Efficacy and Safety of a Once-Daily Fixed-Dose Combination of Abacavir/Lamivudine Compared With Abacavir Twice Daily and Lamivudine Once Daily as Separate Entities in Antiretroviral-Experienced HIV-1 -Infected Patients (CAL30001 Study).” JAIDS: Journal of Acquired Immune Deficiency Syndromes 41 (5): 598–606. doi:10.1097/01.qai.0000214821.33905.5c.